Profile
Sector:
HealthcareCountry:
United StatesIPO:
13 November 2018Website:
http://www.etonpharma.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:00:10 GMTDividend
Analysts recommendations
Institutional Ownership
ETON Latest News
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eaton Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised, this call is being recorded at the company's request.
DEER PARK, Ill., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2024.
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company's New Drug Application (NDA) for ET-400, a proprietary patented formulation of hydrocortisone oral solution, has been accepted by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025.
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, will have its CEO Sean Brynjelsen and CFO James Gruber present at the Citizens JMP Life Sciences Conference in New York.
Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.04 per share a year ago.
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.
DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced that it will report third quarter 2023 financial results on Thursday, November 9, 2023. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
What type of business is Eton Pharmaceuticals?
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
What sector is Eton Pharmaceuticals in?
Eton Pharmaceuticals is in the Healthcare sector
What industry is Eton Pharmaceuticals in?
Eton Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is Eton Pharmaceuticals from?
Eton Pharmaceuticals is headquartered in United States
When did Eton Pharmaceuticals go public?
Eton Pharmaceuticals initial public offering (IPO) was on 13 November 2018
What is Eton Pharmaceuticals website?
https://www.etonpharma.com
Is Eton Pharmaceuticals in the S&P 500?
No, Eton Pharmaceuticals is not included in the S&P 500 index
Is Eton Pharmaceuticals in the NASDAQ 100?
No, Eton Pharmaceuticals is not included in the NASDAQ 100 index
Is Eton Pharmaceuticals in the Dow Jones?
No, Eton Pharmaceuticals is not included in the Dow Jones index
When was Eton Pharmaceuticals the previous earnings report?
No data
When does Eton Pharmaceuticals earnings report?
The next expected earnings date for Eton Pharmaceuticals is 08 November 2024